The main focus of the Genomics Shared Resource (GSR) is to provide expertise and comprehensive service in the area of microarray- and next-generation sequencing (NGS)-based genomics research in both a highly accessible and cost-effective manner for Cancer Center members. The GSR, originally named as the Gene Expression Resource, has been an active Shared Resource in the Cancer Center since the first application for NCI designation in 2001. Since then, we have expanded our portfolio of services to encompass nearly every level of genomics ranging from analysis of cancer genomes with single-base resolution up through standard mRNA and miRNA expression profiling. These also include single nucleotide polymorphism genotyping, epigenomics, and analyses for transcript splice variants, fusion genes, and genomic instability. The GSR has strived to provide our researchers with direct access to the most contemporary genomic applications and state-of-the-art instrumentation. Towards this goal, we possess the capacity to perform profiling on most of the common commercially-available microarray platforms (e.g., Affymetrix, Agilent, lllumina) as well as custom-designed ones. Having recently acquired an lllumina Genome Analyzer llx NGS system, the GSR now also provides this exciting state-of-the-art profiling technology. Importantly, all of these applications can be utilized for translational research as a result of our development of optimized protocols for the analysis of samples from a broad range of sources and of extremely limited amounts. To complement these services and to help achieve productive outcomes from genomics experiments, the GSR also provides extensive data analysis and integrative bioinformatics support and routinely assists in the preparation of the appropriate sections of manuscripts and grant proposals. Taken together, the GSR provides a complete integrative and functional molecular profiling solution to the Cancer Center.
This resource provides leading technologies for the analysis of genes, gene expressions, and DNA-related, cellular material used in examining cancer cells and comparing them to normal cells to gain insights into the cellular processes, events, and materials implicated in cancer. Thus it improves the scientific quality of cancer research and ultimately the development of more effective cancer therapies.
|Kiuru, Maija; Tartar, Danielle M; Qi, Lihong et al. (2018) Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features. J Am Acad Dermatol 79:221-229|
|Pargett, Michael; Albeck, John G (2018) Live-Cell Imaging and Analysis with Multiple Genetically Encoded Reporters. Curr Protoc Cell Biol 78:4.36.1-4.36.19|
|Fishman, Scott M; Carr, Daniel B; Hogans, Beth et al. (2018) Scope and Nature of Pain- and Analgesia-Related Content of the United States Medical Licensing Examination (USMLE). Pain Med 19:449-459|
|Lewis, Daniel D; Chavez, Michael; Chiu, Kwan Lun et al. (2018) Reconfigurable Analog Signal Processing by Living Cells. ACS Synth Biol 7:107-120|
|Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501|
|Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11|
|Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87|
|Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004|
|Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896|
|Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :|
Showing the most recent 10 out of 836 publications